- |||||||||| temelimab (GNbAC1) / GeNeuro, ATA188 / Atara, NurOwn (MSC-NTF) / BrainStorm Cell Therap
Clinical: MS Survival Strategy: Get into any Running trial you can now. Tisch, Nurown, Temelimab, if approved 2025, holds us over until... 2028 Atara ATA-188 (cure?) approved, & more MSCs, Hope Bio. 2030 vaccines (cure?), and NervGen to clean up remaining damage, & more MSCs, Celltex. (Twitter) - Mar 21, 2022
- |||||||||| NurOwn (MSC-NTF) / BrainStorm Cell Therap
CSF biomarkers evaluated by principal component analysis in a NurOwn Phase 3 clinical trial ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1759; P3 ALS is a complex disease in which neurodegeneration, neuroinflammation and failure of intrinsic neuroprotective mechanisms may play an important role1. NurOwn treatment resulted in consistent longitudinal changes in specific CSF neurodegenerative, neuroinflammatory, and neuroprotection biomarkers and within biomarker categories as identified by PCA analysis.PCA analysis of NurOwn treatment effects across biomarker categories contributes to the understanding of its mechanism of action in ALS.
- |||||||||| NurOwn (MSC-NTF) / BrainStorm Cell Therap
Nurown isnt it (Twitter) - Mar 4, 2022
|